{'fraction_non_alphanumeric': 0.06146341463414634, 'fraction_numerical': 0.06, 'mean_word_length': 4.35509138381201, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Incidence of Venous Thromboembolism in Patients with Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes.

BACKGROUND & AIMS
Pancreatic ductal adenocarcinoma (PDAC) is associated with the highest incidence of venous thromboembolism (VTE) of any cancer type. However, little is known about risk factors for VTE or its outcomes in patients with PDAC.


METHODS
We collected data from a prospective, observational study performed at multiple centers in France from May 2014 through November 2018 (the Base Clinico-Biologique de l'Adénocarcinome Pancréatique [BACAP] study) linked to a database of patients with a new diagnosis of PDAC of any stage. Data were collected from 731 patients at baseline and during clinical follow-up or in the event of symptoms. The primary endpoint was the onset of VTE during follow up. The secondary end points were progression-free survival (PFS) and overall survival (OS) times.


RESULTS
During a median follow-up of 19.3 months, 152 patients (20.79%) developed a VTE. The median time from PDAC diagnosis to the onset of VTE was 4.49 months. Cumulative incidence values of VTE were 8.07% (95% CI, 6.31-10.29) at 3 months and 19.21% (95% CI, 16.27-22.62) at 12 months. In multivariate analysis, PDAC primary tumor location (isthmus vs head, hazard ratio [HR], 2.06; 95% CI, 1.09-3.91; P=.027) and stage (locally advanced vs resectable or borderline HR, 1.66; 95% CI 1.10-2.51, P=.016 and metastatic vs resectable or borderline HR, 2.50; 95% CI, 1.64-3.79; P<.001) were independent risk factors for onset of VTE. Patients who developed VTE during follow up had shorter times of PFS (HR, 1.74; 95% CI, 1.19-2.54; P=.004) and OS (HR, 2.02; 95% CI, 1.57-2.60; P<.001).


CONCLUSION
In an analysis of data from the BACAP study, we found that frequent and early onset of VTE after diagnoses of PDAC are associated with significant decreases in times of PFS and OS. Studies are needed to determine whether primary prophylaxis of VTE in patients with PDAC will improve morbidity and mortality related to VTE.